Related Experiment Video
Updated: Jan 22, 2026

In Vivo Inhibition of MicroRNA to Decrease Tumor Growth in Mice
Published on: August 23, 2019
Inhibition of Glucose Transporters and Glutaminase Synergistically Impairs Tumor Cell Growth
Elena S Reckzeh1, George Karageorgis2, Melanie Schwalfenberg2
1Max Planck Institute of Molecular Physiology, Department of Chemical Biology, Otto-Hahn-Strasse 11, 44227 Dortmund, Germany; Technical University Dortmund, Faculty of Chemistry and Chemical Biology, Otto-Hahn-Strasse 6, 44227 Dortmund, Germany.
Abstract:
Cancer cells sustain growth by altering their metabolism to accelerated aerobic glycolysis accompanied by increased glucose demand and employ glutamine as additional nutrient source. This metabolic adaptation induces upregulation of glucose transporters GLUT-1 and -3, and simultaneous targeting of both transporters and of glutamine metabolism may offer a promising approach to inhibit cancer cell growth. We describe the discovery of the very potent glucose uptake inhibitor Glutor, which targets glucose transporters GLUT-1, -2, and -3, attenuates glycolytic flux and potently and selectively suppresses growth of a variety of cancer cell lines. Co-treatment of colon cancer cells with Glutor and glutaminase inhibitor CB-839 very potently and synergistically inhibits cancer cell growth. Such a dual inhibition promises to be particularly effective because it targets the metabolic plasticity as well as metabolic rescue mechanisms in cancer cells.
Insights
Researchers discovered Glutor, a potent inhibitor targeting glucose transporters (GLUT-1, -2, -3), to suppress cancer cell growth. Combining Glutor with a glutaminase inhibitor synergistically halts cancer proliferation by blocking key nutrient sources.
Area of Science:
- Oncology
- Cancer Metabolism
- Biochemistry
Background:
- Cancer cells exhibit altered metabolism, relying on aerobic glycolysis and glutamine.
- This adaptation involves increased glucose transporter expression (GLUT-1, -3).
- Targeting glucose uptake and glutamine metabolism presents a potential anti-cancer strategy.
Purpose of the Study:
- To discover and characterize a novel inhibitor of glucose uptake.
- To evaluate the efficacy of targeting glucose transporters and glutamine metabolism in cancer cells.
Main Methods:
- Discovery of Glutor, a potent inhibitor of glucose transporters (GLUT-1, -2, -3).
- Assessment of Glutor's effect on glycolytic flux and cancer cell line growth.
- Evaluation of synergistic effects of Glutor combined with glutaminase inhibitor CB-839 in colon cancer cells.
Main Results:
- Glutor potently and selectively suppressed the growth of various cancer cell lines.
- Glutor attenuated glycolytic flux.
- Co-treatment with Glutor and CB-839 demonstrated potent and synergistic inhibition of colon cancer cell growth.
Conclusions:
- Targeting glucose transporters with Glutor is a viable strategy for cancer therapy.
- Dual inhibition of glucose uptake and glutamine metabolism offers a synergistic approach to suppress cancer cell growth.
- This dual approach effectively targets cancer's metabolic plasticity and rescue mechanisms.
More Related Videos
Related Concept Videos
Glucose Transporters
Facilitated diffusion-glucose transporters (GLUTs) are encoded by the solute-linked carrier (SLC) family 2, subfamily A gene family, or SLC2A. The 14 GLUT protein members are distributed into three classes:
Secondary Active Transport
Feedback Inhibition
Facilitated Transport
Primary Active Transport
Glucose Homeostasis: Regulation of Blood Glucose
During fasting, when blood glucose levels are low, the pancreas secretes glucagon. it...

